What is the optimal therapy for patients with Helicobacter pylori-negative dyspepsia?
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to Richard Saad.
Explore the source record for details and available documents.
Helicobacter pylori infection is chronic and very common. Its clinical consequences vary widely, ranging from being asymptomatic and clinically insignificant in many cases to causing dyspepsia, peptic ulcer disease, and gastric malignancy in others. Care must be used in deciding whom to test for H pylori infection, as a positive result mandates treatment, making broad-based screening impractical.
Gastroesophageal reflux disease (GERD) is a condition commonly managed in the primary care setting. Patients with GERD may develop reflux esophagitis as the esophagus repeatedly is exposed to acidic gastric contents. Over time, untreated reflux esophagitis may lead to chronic complications such as esophageal stricture or the development of Barrett's esophagus. Barrett's esophagus is a premalignant metaplastic process that typically involves the distal esophagus. Its presence is suspected by endoscopic evaluation of the esophagus, but the diagnosis is confirmed by histologic analysis of endoscopically biopsied tissue. Risk factors for Barrett's esophagus include GERD, white or Hispanic race, male sex, advancing age, smoking, and obesity. Although Barrett's esophagus rarely progresses to adenocarcinoma, optimal management is a matter of debate. Current treatment guidelines include relieving GERD symptoms with medical or surgical measures (similar to the treatment of GERD that is not associated with Barrett's esophagus) and surveillance endoscopy. Guidelines for surveillance endoscopy have been published; however, no studies have verified that any specific treatment or management strategy has decreased the rate of mortality from adenocarcinoma.
Explore the source record for details and available documents.